NCT00114452 is a Phase 1 clinical trial of Provacel in Myocardial Infarction, sponsored by Mesoblast, Inc..

Who is sponsoring NCT00114452?

NCT00114452 is sponsored by Mesoblast, Inc..

What drugs are being tested in NCT00114452?

Interventions in NCT00114452: Provacel, Placebo.

What condition does NCT00114452 study?

NCT00114452 studies Myocardial Infarction.

Is NCT00114452 still recruiting?

NCT00114452 is currently completed. Last updated 10 March 2020.

Last reviewed 2020-03-10 · How we verify

NCT00114452

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety Study of Adult Mesenchymal Stem Cells (MSC) to Treat Acute Myocardial Infarction

Completed Phase 1 Last updated 10 March 2020

What this trial tests

Phase 1 trial testing Provacel in Myocardial Infarction in 60 participants. Completed in 24 April 2008.

Timeline

22 March 2005

Primary endpoint
4 October 2006

24 April 2008

Quick facts

Lead sponsor	Mesoblast, Inc.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	60
Start date	22 March 2005
Primary completion	4 October 2006
Estimated completion	24 April 2008
Sites	15 locations across United States

Drugs / interventions tested

Provacel — full drug profile →
Placebo

Conditions studied

Myocardial Infarction — all drugs for Myocardial Infarction →

Sponsor

Mesoblast, Inc. — full company profile →

Who can join

Adults 21 to 85, any sex, with Myocardial Infarction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to determine whether adult stem cells \[Provacel™(PUMP1)\] are safe and possibly effective in the treatment of acute myocardial infarction (heart attack).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction.
Hare JM, Traverse JH, Henry TD, Dib N, et al · · 2009 · cited 942× · PMID 19958962 · DOI 10.1016/j.jacc.2009.06.055
The therapeutic potential of mesenchymal stem cells for cardiovascular diseases.
Guo Y, Yu Y, Hu S, Chen Y, et al · · 2020 · cited 207× · PMID 32393744 · DOI 10.1038/s41419-020-2542-9
Mesenchymal stem cells in cardiac regeneration: a detailed progress report of the last 6 years (2010-2015).
Singh A, Singh A, Sen D. · · 2016 · cited 137× · PMID 27259550 · DOI 10.1186/s13287-016-0341-0
Update on therapeutic vascularization strategies.
Phelps EA, Garcia AJ. · · 2009 · cited 90× · PMID 19105617 · DOI 10.2217/17460751.4.1.65
Concise Review: Mesenchymal Stem Cells in Cardiovascular Regeneration: Emerging Research Directions and Clinical Applications.
Majka M, Sułkowski M, Badyra B, Musiałek P. · · 2017 · cited 86× · PMID 28836732 · DOI 10.1002/sctm.16-0484
Current stem cell delivery methods for myocardial repair.
Sheng CC, Zhou L, Hao J. · · 2013 · cited 66× · PMID 23509740 · DOI 10.1155/2013/547902
Clinical Use of Mesenchymal Stromal Cells in the Treatment of Acute Graft-versus-Host Disease.
Elgaz S, Kuçi Z, Kuçi S, Bönig H, et al · · 2019 · cited 58× · PMID 31244579 · DOI 10.1159/000496809
Optimization of pre-transplantation conditions to enhance the efficacy of mesenchymal stem cells.
Haque N, Kasim NH, Rahman MT. · · 2015 · cited 56× · PMID 25678851 · DOI 10.7150/ijbs.10567

Verify or expand the search:

Other recruiting trials for Myocardial Infarction

Currently open trials in the same condition.

NCT07257198 — Aspirin-free Strategy With Ticagrelor in Patients With a Myocardial Infarction Treated Medically Alone · Phase 3 · recruiting
NCT07402642 — Effect of Early Educational Intervention on Cardiovascular Risk Factors After Acute Coronary Syndrome · NA · recruiting
NCT07301034 — A Research Study to Look at the Effect of Ziltivekimab on Plaque in the Blood Vessels of the Heart, Compared to Placebo, · Phase 3 · recruiting
NCT07142265 — Evaluation of 1-Year Clinical Outcomes With Early Inclisiran Initiation in Post-MI Patients · recruiting
NCT07138911 — Effect of Home-based Exercise Plan Mediated by Use of Digital Health App on Kinesiophobia and Functional Capacity · NA · recruiting

Other Mesoblast, Inc. trials

Trials by the same sponsor.

NCT02652130 — Safety Follow-up of Treatment With Remestemcel-L in Pediatric Participants Who Have Failed to Respond to Steroid Treatme · Phase 3 · completed
NCT02336230 — A Prospective Study of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Pedia · Phase 3 · completed
NCT02032004 — Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure · Phase 3 · completed
NCT01781390 — Safety Study of Allogeneic Mesenchymal Precursor Cell Infusion in Myocardial Infarction · Phase 2 · completed
NCT01233960 — Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00114452 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mesoblast, Inc.
Last refreshed: 10 March 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00114452.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing